Skip to main content
13/09/2022

The Cardiovascular Diseases group of VHIR participates in the European Congress of Cardiology 2022

Reunió envelliment vascular

13/09/2022

Researchers have presented advances in the field of myocardial infarction, non-compaction cardiomyopathy and genetic aortic pathology, in addition to hosting a meeting between international experts on vascular aging.

Researchers from the Cardiovascular Diseases group at Vall d'Hebron Research Institute (VHIR) presented their latest advances at the congress of the European Society of Cardiology (ESC) held in Barcelona between 26 and 29 August 2022. Of particular interest are the projects in the field of myocardial infarction, non-compaction cardiomyopathy and genetic aortic pathology.

On the other hand, VHIR hosted on August 25 a meeting of the executive team of the European network VascAgeNet, dedicated to vascular aging. The aim of this project is to refine, harmonize and promote the use of vascular aging measures. The meeting, led by Dr. Andrea Guala, researcher of the Cardiovascular Diseases group at VHIR and one of the researchers of the cardiac imaging team and responsible for VascAgeNet training activities, aimed to plan the next steps during the third year of the project.

Vascular aging is the deterioration of vascular structure and function over time and ultimately leads to damage to the heart, brain, kidneys, and other organs. Vascular aging encompasses the cumulative effect of all cardiovascular risk factors on the arterial wall over a lifetime and, therefore, can help identify individuals at elevated cardiovascular risk early in the development of the disease.

Related news

The study analyzes the scientific evidence on the harmful effect of environmental pollution and heavy metals on cardiovascular health and summarizes the strategies for its prevention and treatment.

Els estudis avançaran en els camps de les malalties digestives, el VIH, la fatiga crònica, les patologies cardíaques, l’hepatitis, la diabetis i l’oftalmologia.

The Interuniversity Research led by the NeuroPhar laboratory of the UPF has discovered that modulating the endocannabinoid system considerably improves some of the effects of the pathology.

Related professionals

Andrea Guala

Andrea Guala

Postdoctoral researcher
Cardiovascular Diseases
Read more
Inma Salomón Castaño

Inma Salomón Castaño

Cardiovascular Diseases
Read more
Ignacio Ferreira González

Ignacio Ferreira González

Head of group
Cardiovascular Diseases
Read more
Berta Miranda Barrio

Berta Miranda Barrio

Predoctoral researcher
Cardiovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.